| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EXTENDED REPORT |
1 University Medicine Berlin, Campus Benjamin Franklin, Germany
2 Rheumatology Medical Centre Ruhrgebiet, Herne, Germany
3 German Rheumatism Research Centre, Berlin, Germany
4 Schlosspark Clinic, Berlin, Germany
5 Charité Hospital, Humboldt University, Berlin, Germany
6 Berlin-Buch Hospital, Berlin Germany
7 Ludwig-Maximilians-University, Munich, Germany
8 Heinrich-Heine-University, Düsseldorf, Germany
9 Immanuel Hospital, Berlin, Germany
10 Medical University, Hannover, Germany
Correspondence to:
Correspondence to:
Professor J Braun
Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652 Herne, Germany; J.Braun{at}Rheumazentrum-Ruhrgebiet.de
Objective: To obtain results of the second year extension of an original 3 month randomised, placebo controlled trial (and the 1 year extension study) assessing the use of infliximab, a monoclonal antibody to tumour necrosis factor 
, for the treatment of patients with ankylosing spondylitis (AS).
Methods: Of the 54 patients with AS who completed the first year of the study, 52 continued to receive infliximab 5 mg/kg every 6 weeks up to week 102. The primary end point was the proportion of patients achieving at least 50% improvement from baseline in the Bath AS Disease Activity Index (BASDAI) at week 102. Other assessments included patient and physician global assessments, quality of life as assessed by Short Form-36, Bath AS Functional Index, Bath AS Metrology Index, and C reactive protein (CRP).
Results: Improvement in signs and symptoms of AS seen during the first year of the study was sustained during the second year. Forty nine patients (71% of 69 enrolled patients and 49/52 (94%) patients who started year 2) completed the study up to week 102. Thirty (58%) patients achieved at least 50% improvement from baseline in the BASDAI score at week 102. Scores for other efficacy assessments were similar at weeks 54 and 102. Median CRP levels remained low at weeks 54 and 102 (3.9 and 4.3 mg/l, respectively). Side effects during the second year of the study were similar to those of the first year of treatment with infliximab.
Conclusions: Patients with AS treated for 2 years with infliximab 5 mg/kg exhibited a good and durable clinical response.
Abbreviations: AS, ankylosing spondylitis; ASAS, Assessment in Ankylosing Spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath AS Functional Index; BASMI, Bath AS Metrology Index; CRP, C reactive protein; DMARDs, disease modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; ITT, intention to treat; NSAIDs, non-steroidal anti-inflammatory drugs; SF-36, Short Form-36; TNF, tumour necrosis factor
Keywords: tumour necrosis factor ; ankylosing spondylitis; infliximab
This article has been cited by other articles:
|
|
 |
|
  E. K. Li, J. F. Griffith, V. W. Lee, Y.-X. Wang, T. K. Li, K. K. Lee, and L.-S. Tam Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation Rheumatology, September 1, 2008; 47(9): 1358 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Coates, L. S. Cawkwell, N. W. F. Ng, A. N. Bennett, D. J. Bryer, A. D. Fraser, P. Emery, and H. Marzo-Ortega Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis Rheumatology, June 1, 2008; 47(6): 897 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Braun, X Baraliakos, J Listing, C Fritz, R Alten, G Burmester, A Krause, S Schewe, M Schneider, H Sorensen, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor {alpha} therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response Ann Rheum Dis, March 1, 2008; 67(3): 340 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii2 - iii22. [Full Text] [PDF]
|
|
|
|
|
|
X. Baraliakos, J. Listing, J. Brandt, H. Haibel, M. Rudwaleit, J. Sieper, and J. Braun Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-{alpha} antibody infliximab Rheumatology, September 1, 2007; 46(9): 1450 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X Baraliakos, J Listing, M Rudwaleit, H Haibel, J Brandt, J Sieper, and J Braun Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes Ann Rheum Dis, July 1, 2007; 66(7): 910 - 915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y Yazici and H Yazici A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor {alpha} inhibitors Ann Rheum Dis, January 1, 2007; 66(1): 124 - 127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, P Emery, E C Keystone, M H Schiff, P L C M van Riel, M E Weinblatt, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006 Ann Rheum Dis, November 1, 2006; 65(suppl_3): iii2 - iii15. [Full Text] [PDF]
|
|
|
|
|
|
L. Gossec, A. Le Henanff, M. Breban, E. Vignon, P. Claudepierre, V. Devauchelle, D. Wendling, E. Lespessailles, L. Euller-Ziegler, J. Sibilia, et al. Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up Rheumatology, July 1, 2006; 45(7): 859 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Massara, P. L. Cavazzini, and F. Trotta In SAPHO syndrome anti-TNF-{alpha} therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations Rheumatology, June 1, 2006; 45(6): 730 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Zochling, D van der Heijde, R Burgos-Vargas, E Collantes, J C Davis Jr, B Dijkmans, M Dougados, P Geher, R D Inman, M A Khan, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis Ann Rheum Dis, April 1, 2006; 65(4): 442 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zochling, J. Brandt, and J. Braun The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis Rheumatology, December 1, 2005; 44(12): 1483 - 1491. [Full Text] [PDF]
|
|
|
|
|
|
J. Sieper, X. Baraliakos, J. Listing, J. Brandt, H. Haibel, M. Rudwaleit, and J. Braun Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab Rheumatology, December 1, 2005; 44(12): 1525 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv2 - iv14. [Full Text] [PDF]
|
|
|
|
|
|
X Baraliakos, J Listing, M Rudwaleit, J Brandt, J Sieper, and J Braun Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor {alpha} antibody infliximab Ann Rheum Dis, October 1, 2005; 64(10): 1462 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X Baraliakos, R Landewe, K-G Hermann, J Listing, W Golder, J Brandt, M Rudwaleit, M Bollow, J Sieper, D van der Heijde, et al. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging Ann Rheum Dis, May 1, 2005; 64(5): 730 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Braun, X. Baraliakos, J. Brandt, J. Listing, A. Zink, R. Alten, G. Burmester, E. Gromnica-Ihle, H. Kellner, M. Schneider, et al. Persistent clinical response to the anti-TNF-{alpha} antibody infliximab in patients with ankylosing spondylitis over 3 years Rheumatology, May 1, 2005; 44(5): 670 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Marcovitch What's new this month in BMJ Journals BMJ, March 12, 2005; 330(7491): 564 - 564. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
